Biotech Archives - Page 134 of 795

1 minute read

Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal

January 8, 11:18 AM

Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi

AMAM

1 minute read

Why Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today?

By Vandana Singh

January 8, 11:14 AM

Vincerx Pharma Inc (NASDAQ: VINC) shares are trading higher after the company released clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for

VINC

1 minute read

Summit Therapeutics Announces Updated Phase II Data For Ivonescimab At 42nd Annual J.P. Morgan Healthcare Conference

By Benzinga Newsdesk

January 8, 10:36 AM

Phase II 24-Month OS Rate of 64.8% in 1L Squamous NSCLC PatientsPhase II mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC PatientsCatalyst Events Expected in Q2 2024 for Two Randomized Phase III Trials Evaluating

SMMT

3 minute read

FDA
News

Owlet Transforms Infant Care With The Launch Of Two FDA-Cleared Devices, Dream Sock And BabySat

By Benzinga Newsdesk

January 8, 10:03 AM

These new, innovative devices empower caregivers to monitor what matters most with reliable, medical-grade technology.Owlet, Inc. ("Owlet" or the "Company") (NYSE:OWLT), the pioneer of smart infant monitoring, today

OWLT

2 minute read

Incyte Highlights Growth Opportunities And Provides Business Updates At The 42nd Annual J.P. Morgan Healthcare Conference

By Benzinga Newsdesk

January 8, 10:02 AM

Presentation underscores potential of several high-impact launches across Oncology and Inflammation & Autoimmunity to drive sustainable long-term growthCompany announces new positive topline results from Phase 2

INCY

3 minute read

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue And Provides Corporate Updates; Sees Q4 Revenue $69M-$71M Vs $68.27M Est.; FY23 Revenue $178M-$180M Vs $185.4M Est.; LIVMARLI Net Products Sales Of $141M-143M Expected For 2023

By Benzinga Newsdesk

January 8, 9:58 AM

- $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited- LIVMARLI net products sales of $141-143 million expected for 2023, representing approximately 89%

MIRM

2 minute read

Artelo Biosciences Announces Selection Of Worldwide Clinical Trials As Clinical Research Organization To Support First-In-Human Study Of ART26.12

By Benzinga Newsdesk

January 8, 9:47 AM

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological

ARTL

3 minute read

Editas Medicine Highlights 2024 Anticipated Milestones And Strategic Priorities At The J.P. Morgan Healthcare Conference

By Benzinga Newsdesk

January 8, 9:35 AM

Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed

EDIT

2 minute read

Landos Biopharma To Present New Data On Immunometabolism At The 19th Annual Congress Of The European Crohn’s And Colitis Organisation

By Benzinga Newsdesk

January 8, 9:26 AM

Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos" or the "Company"), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that six abstracts were

LABP

6 minute read

Praxis Precision Medicines Provides Update On Advancing Clinical Stage Portfolio; Recently Announced Licensing Partnership With Tenacia Biotechnology To Develop And Commercialize Ulixacaltamide In Greater China With Total Consideration Over $275M

By Benzinga Newsdesk

January 8, 9:25 AM

Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion of 45 mg

IONS